Merck KGaA, Darmstadt, Germany Establishes Digital Ethics Advisory Panel
Panel will provide guidance around evolving digital business models.
Merck KGaA, Darsmtadt Germany, has created a Digital Ethics Advisory Panel, designed to provide guidance around evolving digital business models.
The Merck Digital Ethics Advisory Panel will address digital ethics questions for all three business sectors of Merck KGaA, Darmstadt, Germany and provide external guidance and expertise on complex ethical matters around data usage, algorithms, and new digital innovations. Specifically, the panel will ensure that the company develops new digital technologies responsibly and addresses potential ethical issues arising from the use of these technologies. The panel will consist of academic and industry experts in the fields of digital ethics, legal and regulatory, big data technology, digital health, medicine and data governance from the US and Europe.
The panel’s first responsibility is to develop a Digital Code of Ethics (Code) that will serve as a governing framework and guide how the panel provides counsel. The Code will define essential digital ethics principles for Merck KGaA, Darmstadt, Germany that will serve as guidance for the company.
“As a rapidly developing field, digital ethics is a new, complex territory for many,” said Sarah Becker, Founder & Managing Partner of Institute for Digital Transformation in Healthcare (idigiT), and a member of the panel. “As the landscape continues to evolve, we as an industry must be diligent about meeting rigorous ethical standards, and expert forums such as the Merck Digital Ethics Advisory Panel are key to that effort.”
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
